Skip to main content
SpringerLink
Log in

Selective inhibition of group II phospholipase A2 by quercetin

  • Original Articles
  • Published:
Inflammation Aims and scope Submit manuscript

Abstract

The influence of quercetin, chlorpromazine, aristolochic acid, and indomethacin on group I phospholipase A2 (PLA2) from porcine pancreas and on group II PLA2 fromVipera russelli was compared. Quercetin and chlorpromazine were found to inhibit PLA2 activity in lower concentrations (< 100μM), while aristolochic acid and indomethacin were inhibitory only in higher concentrations (> 100μM). The order of potency againstVipera PLA2 was: quercetin >chlorpromazin aristolochic acid > indomethacin, while the order of potency against pancreatic PLA2 was: chlorpromazine > aristolochic acid > indomethacin> quercetin. Thus, quercetin was a potent inhibitor towards group II PLA2 (IC50=2μM), but a very weak inhibitor against group I PLA2, with maximum 30% inhibition. Aristolochic acid and indomethacin were three to four times more potent towards group II PLA2 than towards group I PLA2, while chlorpromazine was equally potent towards the two PLA2 types. Quercetin and chlorpromazine were also tested against two PLA2 fractions purified from the plasma of septic shock patients; chlorpromazine was then equally potent towards the two PLA2 fractions, whereas quercetin was a potent inhibitor of only one of the two PLA2 fractions (IC50=4μM). Together, these results indicate that (1) different PLA2 inhibitors have different potency depending on which type of PLA2 they are used against, (2) quercetin selectively inhibits group II PLA2 and may therefore be used to discriminate between different PLA2 forms in biological materials, and (3) both PLA2 of group I and group II are present in septic shock plasma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chang, J., J. H. Musser, andH. McGregor. 1987. Phospholipase A2: Function and pharmacological regulation.Biochem. Pharmacol. 36:2429–2436.

    Google Scholar 

  2. Pruzanski, W., E. C. Keystone, B. Sternby, C. Bombardier, K. M. Snow, andP. Vadas. 1988. Serum phospholipase A2 correlates with disease activity in rheumatoid arthritis.J. Rheumatol. 15:1351–1355.

    Google Scholar 

  3. Vadas, P., W. Pruzanski, andE. Stefanski. 1988. Extracellular phospholipase A2: Causative agent in circulatory collapse of septic shock?Agents Actions 24:320–325.

    Google Scholar 

  4. Crowl, R. M., T. J. Stoller, R. R. Conroy, andC. R. Stoner. 1991. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response.J. Biol. Chem. 266:2647–2651.

    Google Scholar 

  5. Pruzanski, W., andP. Vadas. 1991. Phospholipase A2-a mediator between proximal and distal effectors of inflammation.Immunol. Today 12:143–146.

    Google Scholar 

  6. Davidson, F. F., andE. A. Dennis. 1990. Evolutionary relationships and implications for the regulation of phospholipase A2 from venom to human secreted forms.J. Mol. Evol. 31:228–238.

    Google Scholar 

  7. Kramer, R. M., C. Hession, B. Johansen, G. Hayes, P. McGray, E. P. Chow, R. T. Tizard, andR, B. Pepinsky. 1989. Structure and properties of a human nonpancreatic phospholipase A2.J. Biol. Chem. 264:5768–5774.

    Google Scholar 

  8. Ono, T., H. Tojo, S. Kuramitsu, H. Kagamiyama, andM. Okamoto. 1988. Purification and characterization of a membrane-associated phospholipase A2 from rat spleen. Its comparison with a cytosolic phospholipase A2 S-1.J. Biol. Chem. 263:5732–5738.

    Google Scholar 

  9. Nakano, T., andH. Arita. 1990. Enhanced expression of group II phospholipase A2 gene in the tissues of endotoxin shock rats and its suppression by glucocorticoid.FEBS Lett. 273:23–26.

    Google Scholar 

  10. Matsuda, Y., M. Ogawa, T. Shibata, K. Nakaguchi, J.-I. Nishijima, C. Wakasugi, andT. Mori. 1987. Distribution of immunoreactive pancreatic phospholipase A2 (IPPL-2) in various human tissues.Res. Commun. Chem. Pathol. Pharmacol. 58:281–284.

    Google Scholar 

  11. Wright, G. W., C. E. Ooi, J. Weiss, andP. Elsbach. 1990. Purification of a cellular (granulocyte) and extracellular (serum) phospholipase A2 that participate in the destruction ofEscherichia coli in a rabbit inflammatory exudate.J. Biol. Chem. 265:6675–6681.

    Google Scholar 

  12. Minami, T., H. Tojo, Y. Shinomura, S. Tarui, andM. Okamoto. 1992. Raised serum activity of phospholipase A2 immunochemically related to group II enzyme in inflammatory bowel disease: Its correlation with disease activity of Crohn's disease and ulcerative colitis.Gut 33:914–921.

    Google Scholar 

  13. Vadas, P., K. Scott, G. Smith, I. Rajkovic, E. Stefanski, B. D. Schouten, R. Singh, andW. Pruzanski. 1992. Serum phospholipase A2 enzyme activity and immunoreactivity in a prospective analysis of patients with septic shock.Life Sci. 50:807–811.

    Google Scholar 

  14. Kitigawa, M., T. Hayakawa, T. Kondo, T. Shibata, Y. Sakai, H. Sobajima, H. Ishiguro, M. Tanikawa, Y. Nakae, S. Kameya, andA. Noda. 1991. Elevation of serum phospholipase A2 in patients at an intensive care unit.Int. J. Pancreatol. 10:279–286.

    Google Scholar 

  15. Marshall, L. A., J. Bauer, M. L. Sung, andJ. Y. Chang. 1991. Evaluation of antirheumatic drugs for their effect in vitro on purified human synovial fluid phospholipase A2.J. Rheumatol. 18:59–65.

    Google Scholar 

  16. Mobilio, D., andL. A. Marshall. 1989. Recent advances in the design and evaluation of inhibitors of phospholipase A2.Annu. Rep. Med. Chem. 24:157–166.

    Google Scholar 

  17. Patriarca, P., S. Beckerdite, andP. Elsbach. 1972. Phospholipase and phospholipid turnover inEscherichia coli spheroplasts.Biochim. Biophys. Acta 260:593–600.

    Google Scholar 

  18. Lindahl, M., C. de Wit, B. Weström, H. von Schenck, andC. Tagesson. 1991. Demonstration of a phospholipase A2 inhibitor in human plasma and in plasma from the european hedgehog (Erinaceus europaeus).Int. J. Biochem. 23:287–292.

    Google Scholar 

  19. Vadas, P., E. Stefanski, andW. Pruzanski. 1986. Potential therapeutic efficacy of inhibitors of human phospholipase A2 in septic shock.Agents Actions 19:194–202.

    Google Scholar 

  20. Lindahl, M., H. von Schenck, andC. Tagesson. 1989. Isolation and characterization of phospholipase A2 from rat lung with affinity chromatography and two-dimensional gel electrophoresis.Biochim. Biophys. Acta 1005:282–288.

    Google Scholar 

  21. Nicholson, D. P. 1983. Corticosteroids in treatment of septic shock and the adult respiratory distress syndrome.Med. Clin. North Am. 67:717–724.

    Google Scholar 

  22. Chang, J., M. D. Skowronek, M. L. Cherney, andA. J. Lewis. 1984. Differential effects of putative lipoxygenase inhibitors on arachidonic acid metabolism in cell-free and intact cell preparations.Inflammation 8:143–155.

    Google Scholar 

  23. Vishwanath, B. S., R. M. Kini, andT. V. Gowda. 1987. Characterization of three edemainducing phospholipase A2 enzymes from habu (Trimeresurus flavoviridis) venom and their interaction with the alkaloid aristolochic acid.Toxicon 25:501–515.

    Google Scholar 

  24. Vishwanath, B. S., A. G. A. Rao, andT. V. Gowda. 1987. Interaction of phospholipase A2 fromVipera russelli venom with aristolochic acid: A circular dichroism study.Toxicon 25:939–946.

    Google Scholar 

  25. Rosenthal, M. D., B. S. Vishwanath, andR. C. Franson. 1989. Effects of aristolochic acid on phospholipase A2 activity and arachidonate metabolism of human neutrophils.Biochim. Biophys. Acta 1001:1–8.

    Google Scholar 

  26. Waite, M. 1987. Pancreatic and snake venom phospholipases A2.In The Phospholipases. Handbook of Lipid ReseArch. Vol. 5. D. J. Hanahan, editor. Plenum Press, New York. 155–190.

    Google Scholar 

  27. Lindahl, M. 1990. Phospholipase A2 activation and inflammatory reactions in the lung. Linköping University Medical Dissertations No. 323, Linköping, Sweden.

    Google Scholar 

  28. Calhoun, W., J. Yu, A. Sung, T. T. Chau, L. A. Marshall, B. M. Weichman, andR. P. Carlson. 1989. Pharmacologic modulation of D-49 phospholipase A2-induced paw edema in the mouse.Agents Actions 27:418–421.

    Google Scholar 

  29. Lanni, C., andE. L. Becker. 1985. Inhibition of neutrophil phospholipase A2 by p-bromophenacyl bromide, nordihydroguaiaretic acid, 5,8,11,14-eicostetetrayenoic acid and quercetin.Int. Arch. Allergy. Appl. Immun. 76:214–217.

    Google Scholar 

  30. Fawzy, A. A., B. S. Vishwanath, andR. C. Franson. 1988. Inhibition of human nonpancreatic phospholipase A2 by retinoids and flavonoids. Mechanism of action.Agents Actions 25:394–400.

    Google Scholar 

  31. Baur, M., T. O. Schmid, andB. Landauer. 1989. Role of phospholipase A in multiorgan failure with special reference to ARDS and acute renal failure (ARF).Klin. Wochenschr. 67:196–202.

    Google Scholar 

  32. Hoffmann, G. E., andW. G. Guder. 1989. Serum phospholipase-regulatory and pathophysiological aspects.Klin. Wochenschr. 67:144–148.

    Google Scholar 

  33. Vadas, P., W. Pruzanski, E. Stefanski, andB. Sternby. 1990. Compartmental heterogeneity of soluble phospholipase A.Inflammation 14:173–183.

    Google Scholar 

  34. Eskola, J. U., T. J. Nevalainen, andP. Kortesuo. 1988. Immunoreactive pancreatic phospholipase A2 and catalytically active phospholipase A2 in serum from patients with acute pancreatitis.Clin. Chem. 34:1052–1054.

    Google Scholar 

  35. Pruzanski, W., S. Saito, E. Stefanski, andP. Vadas. 1991. Comparison of group I and II soluble phospholipase A2 activities on phagocytic functions of human polymorphonuclear and mononuclear phagocytes.Inflammation 15:127–135.

    Google Scholar 

  36. Hanasaki, K., andH. Arita. 1992. Characterization of a high affinity binding site for pancreatic-type phospholipase A2 in the rat. Its cellular and tissue distribution.J. Biol. Chem. 267:6414–6420.

    Google Scholar 

  37. Murakami, M., I. Kudo, andK. Inoue. 1991. Eicosanoid generation from antigen-primed mast cells by extracellular mammalian 14-kDa group II phospholipase A2.FEBS Lett. 294:247–251.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Clinical Chemistry and Occupational Medicine, University of Linköping, S-581 85, Linköping, Sweden

    Mats Lindahl & Christer Tagesson

Authors
  1. Mats Lindahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christer Tagesson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lindahl, M., Tagesson, C. Selective inhibition of group II phospholipase A2 by quercetin. Inflammation 17, 573–582 (1993). https://doi.org/10.1007/BF00914195

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00914195

Keywords

Search

Navigation